Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

Authors :: Alexa B. Kimball
Melissa J. Danesh
Source :: Journal of the American Academy of Dermatology. 74:190-192
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.
Abstract: Brodalumab is a human monoclonal antibody developed by Amgen, Inc. to treat inflammatory diseases. In May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior"... Language: en

Subjects :: 030203 arthritis & rheumatology
medicine.medical_specialty
business.industry
Brodalumab
Poison control
Context (language use)
Dermatology
Suicide prevention
Occupational safety and health
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Depression (economics)
Injury prevention
Medicine
medicine.symptom
business
Psychiatry
Suicidal ideation

Full Text Access

Tools